We are developing potential medicines to improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
We have conducted more than 50 clinical trials as we strive to bring important new medicines to patients with diseases like ALS, heart failure, HCM and SMA.
Q3 2021 Cytokinetics, Inc. Earnings Conference Call
Nov 3, 2021 4:30 PM EDT
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>
SOUTH SAN FRANCISCO, Calif. , Nov. 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a fireside chat at the Piper Sandler 33 rd Annual Virtual Healthcare Conference
Analysis from GALACTIC-HF Shows Treatment with Omecamtiv Mecarbil Associated with Significant Reduction in the Risk of Stroke Data on Analog to CK-3828136 Adds Preclinical Support for Cardiac Troponin Activation as Novel Mechanism to Increase Cardiac Function without Impacting Cardiac Efficiency
SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced two presentations at the American Heart Association (AHA) Scientific Sessions 2021, taking place online from November 13, 2021 – November 15, 2021 , including the presentation
Submission of NDA for Omecamtiv Mecarbil on Track to Occur in Q4 2021 Start-Up Activities Underway for SEQUOIA-HCM Enrollment Complete in Cohort 3 of REDWOOD-HCM; Results Expected in Q1 2022 SOUTH SAN FRANCISCO, Calif. , Nov. 03, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK)
